Home > Insider Trading > Filing (0000899243-18-004892)

Filing Details

Accession Number:: 0000899243-18-004892
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-02-21 18:10:32
Reporting Period:: 2018-02-16

Accepted Time:: 2018-02-21 18:10:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1629137	Global Blood Therapeutics Inc.	GBT	Pharmaceutical Preparations (2834)	274825712

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1650126	Jung Choi	C/O Global Blood Therapeutics, Inc. 171 Oyster Point Blvd., Suite 300 South San Francisco CA 94080	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2018-02-16	1,600	$62.95	140,877	No	4	S	Direct
Common Stock	Acquisiton	2018-02-16	198	$3.40	141,075	No	4	M	Direct
Common Stock	Acquisiton	2018-02-16	601	$3.40	141,676	No	4	M	Direct
Common Stock	Acquisiton	2018-02-16	601	$3.40	142,277	No	4	M	Direct
Common Stock	Disposition	2018-02-16	1,400	$62.95	140,877	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2018-02-16	198	$0.00	198	$3.40
Common Stock	Stock Option (Right to Buy)	Disposition	2018-02-16	601	$0.00	601	$3.40
Common Stock	Stock Option (Right to Buy)	Disposition	2018-02-16	601	$0.00	601	$3.40

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
75,558	2025-04-08	No	4	M	Direct
4,478	2025-04-08	No	4	M	Direct
4,478	2025-04-08	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	25,000	Indirect	By Trust

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter.
25% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.
On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.
On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.